Biotechnology

Medincell's latest results show a planned loss but reveal a strategic shift to recurring royalties, fueled by UZEDY®'s success and a pipeline set for growth.

A forgotten corner of oncology is set for a 14.2% CAGR. A new wave of drugs for chemo-induced neuropathy signals a major market realignment.

Nomic and the Wellcome Sanger Institute unite to profile immune diversity in underrepresented populations, using proteomics to bridge the gap from gene to function.

As nations race to finalize a pandemic treaty, a battle over enforceable equity threatens to derail the entire process. Will it be a new era of cooperation or a repeat of past failures?

The inaugural Young American Scientists list spotlights brilliant minds. But behind the accolades lies a system in crisis, threatening America's innovation.

A major merger backed by private equity signals a new era for pharmaceutical training, blending AI, behavioral science, and launch expertise to tackle industry complexity.

With a novel non-hallucinogenic drug, Enveric Biosciences heads to the BIO convention seeking partners. Can its unique science secure its future?

The PD-L1 biomarker testing market is set to double by 2036, fueling a revolution in cancer care. But as innovation races ahead, who gets left behind?

A new approval in Abu Dhabi for NeOnc's NEO212 isn't just a clinical step; it's a strategic play in the high-stakes world of brain cancer therapy.

A new manufacturing patent for pelareorep de-risks Oncolytics' path to market, protecting the drug until 2044 and signaling commercial readiness.

A pilot study shows light therapy improving memory in MCI patients, fueling the at-home neurotech boom. But can Vielight turn scientific promise into market reality?

Komodo Health restructures its C-suite, signaling a major shift in healthcare. It's no longer about AI hype; it's about enterprise-scale dominance.

A record $1.15M campaign for blood cancer reveals a new playbook where executive influence, not just corporate checks, drives profound social impact.

In a strategic pivot, GeneDx brings in former Quest and Thermo Fisher exec Mark Gardner to translate its genomic leadership into commercial dominance.

Eli Lilly's strategic buyout of a Texas biotech isn't just a deal; it's a bet on a new scientific paradigm to solve the chronic pain crisis without opioids.

With patient dosing underway for its fibroblast-based DFU therapy, FibroBiologics is testing a new paradigm: healing chronic wounds from within.

Quoin Pharma's new data for a rare skin disease shows life-changing results in children, offering hope for families. What do the numbers really mean?

With veteran investor Travis Read as new President & COO, AmMax Bio signals a major push to accelerate its promising antibody-drug conjugate pipeline.

BioAge Labs starts a Phase 2 trial for BGE-102, an oral drug targeting inflammation to reduce heart risk, a strategy that could redefine cardiovascular care.

A new partnership between Innoviva and Dr. Reddy's aims to bring a vital antibiotic, XACDURO®, to regions where a deadly hospital infection is rampant.